Phoenix Rising tells QMUL: release the PACE trial data
Mark Berry, Acting CEO of Phoenix Rising, presents the Board of Directors’ open letter to Queen Mary University of London (QMUL) urging them to release the PACE trial data, and hopes that other non-UK organisations will join British charities in the same request...
Discuss the article on the Forums.

Three Rituximab studies: MS, paediatric demyelinating disease and autoimmune/inflammation

Discussion in 'Rituximab: News and Research' started by Firestormm, Jul 10, 2014.

  1. Firestormm

    Firestormm Guest

    Messages:
    5,823
    Likes:
    6,015
    Cornwall England
    Posted by Dr Shepherd (MEA Medical Advisor) to Co-cure:

    Note: The third study above was featured by @Nielk on her thread here yesterday.
     
    NK17, Valentijn and taniaaust1 like this.

See more popular forum discussions.

Share This Page